Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042689 · ClinicalTrials.gov registry record · Phase 1
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03042689: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03042689 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03042689, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative neoplasms) The intervention involved in this study is: -Regorafenib (Stivarga)
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042689
The ClinicalTrials.gov registry entry for NCT03042689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT03042689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03042689 about?
NCT03042689 is a clinical study titled "Study of Regorafenib in Patients With Advanced Myeloid Malignancies". This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative neoplasms) The intervention involved in this study is: -Regorafenib (Stivarga)
What is the current status of trial NCT03042689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-04-17. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT03042689?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT03042689?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.